SynthesisBMJ open2021
Can
Synthesis in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Diagnostic accuracy of 18F-FDG PET/CT scan in distant metastasis staging of non-small cell lung cancer: A meta-analysis.Medicine · 2026Pooled it
- Predictive value ofFrontiers in oncology · 2024Pooled it
- Preoperative PET/CT phenotype of gastric-type endocervical adenocarcinoma: integrated morphological, metabolic, serological, and explainable machine-learning analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Association between the presence of EGFR or ALK mutations and the location of primary non-small cell lung cancer, as well as metabolic activity observed onOncology letters · 2026Article
- Automated cGMP Radiosynthesis of [Molecular imaging and biology · 2026Article
- Prognostic Role ofCancers · 2026Article
- Impact assessment of [18F]FDG PET/CT in predicting EGFR gene mutation status in patients with lung adenocarcinoma using recovery coefficient-based correction of semi-quantitative and volume-based PET metrics.Nuklearmedizin. Nuclear medicine · 2026Article
- Tumor Characterization Using [Pharmaceuticals (Basel, Switzerland) · 2026Article
- Transfer learning-based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in lung adenocarcinoma.BMC medical imaging · 2024Article
- A Novel Dual-labeled Peptide for Multimodal Imaging of EGFR with L858R Mutation.Current radiopharmaceuticals · 2024Article
- The predictive value of [EJNMMI research · 2023Article
- A novel dual-labeled small peptide as a multimodal imaging agent for targeting wild-type EGFR in tumors.PloS one · 2022Article
- Recent and current advances in PET/CT imaging in the field of predicting epidermal growth factor receptor mutations in non-small cell lung cancer.Frontiers in oncology · 2022Review
- Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study aimed to explore the diagnostic significance of
designA systematic review and meta-analysis. DATA SOURCES: The PubMed, EMBASE and Cochrane library databases were searched from the earliest available date to December 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: The review included primary studies that compared the mean maximum of standard uptake value (SUV DATA EXTRACTION AND SYNTHESIS: The main analysis was to assess the sensitivity and specificity, the positive diagnostic likelihood ratio (DLR+) and DLR-, as well as the diagnostic OR (DOR) of SUV
resultsAcross 15 studies (3574 patients), the pooled sensitivity for
conclusionMeta-analysis results showed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.